Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Sofinnova Investments’ Jim Healy says biotech innovation is thriving but is skeptical about artificial intelligence’s ability ...

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

It might pull it off, provided several things fall right in place.

Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

A weekly newsletter focusing on the most important news in health and biotech. Founded at the Massachusetts Institute of ...

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.